Correspondence

ap-hop-paris.fr Background and Methods Cardiac troponin I (cTnI) is well recognized as a specic marker for myocardial infarction. A fully automated, random access, uorescent immunoassay for cTnI was evaluated in comparison with an established assay (Stratus cTnI) using samples from healthy subjects and from patients with cardiac disease. Results The detection and precision were acceptable, and no interference was observed from bilirubin, triglycerides, haemoglobin, rheumatoid factor, drugs (aspirin, dopamine, digoxin) or heparin. Results on the Kryptor cTnI assay correlated with those on the Stratus II cTnI assay. The optimum Kryptor cTnI concentration for acute myocardial infarction was 0¢63 mg/L, with a sensitivity of 89 % [95 % condence interval (CI): 75¢9--96¢3] and specicity of 98¢9 % (95 % CI: 93¢9--99¢8). Conclusion Kryptor cTnI immunoassay is suitable for use in the diagnosis of myocardial infarction. Ann Clin Biochem 2002; 39: 145- 147 Clinical interest in cardiac troponin I (cTnI) for the diagnosis of myocardial infarction1 has led to the development of new assays. We evaluate here the analytical and clinical performance of the Kryptor cTnI assay (BRAHMS, Sartrouville, France) and compare it with the Stratus II cTnI assay (Dad